1h Free Analyst Time
The myocardial infarction (Mi) therapeutics market is forecasted to grow by USD 1.92 billion during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the myocardial infarction (Mi) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of mi, increased adoption of novel antithrombotics, and favorable reimbursement schemes.
The myocardial infarction (Mi) therapeutics market is segmented as below:
By Product
- Antithrombotics
- Vasodilators
- Thrombolytics
- Others
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the myocardial infarction (Mi) therapeutics market covers the following areas:
- Myocardial Infarction (Mi) Therapeutics Market sizing
- Myocardial Infarction (Mi) Therapeutics Market forecast
- Myocardial Infarction (Mi) Therapeutics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global myocardial infarction (Mi) therapeutics market: Amgen Inc., AstraZeneca Plc, Athera Biotechnologies AB, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, CHIESI Farmaceutici SpA, CSL Ltd., Eli Lilly and Co., Ever Supreme Bio Technology, F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., and Sanofi SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing risk factors for mi."
According to the report, one of the major drivers for this market is the rising incidence of mi.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Athera Biotechnologies AB
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- CeleCor Therapeutics
- CHIESI Farmaceutici SpA
- CSL Ltd.
- Eli Lilly and Co.
- Ever Supreme Bio Technology
- F. Hoffmann La Roche Ltd.
- Faraday Pharmaceuticals
- Idorsia Pharmaceuticals Ltd.
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Mesoblast Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
